Once COVID-19 Candidate, Veru's Sabizabulin Shows Encouraging Action In Animal Studies Against Poxvirus

• Veru Inc (NASDAQ: VERU) announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus.

• Poxvirus infections typically result in lesions, skin nodules, or disseminated rash formation.

• The data demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells.

• Treatment of BSC40 cells (African green monkey kidney cells) with different concentrations of sabizabulin before inoculation with vaccinia virus demonstrated a drug dose-dependent inhibition of infectious extracellular enveloped virus (EEV) release (R2 value=0.9573) with an inhibition concentration of 50% and 90% of 24.3nM and 37.8nM concentrations of sabizabulin, respectively.

• BSC40 cells were treated with different concentrations of sabizabulin before inoculation with vaccinia virus at a low multiplicity of infection to assess the ability of sabizabulin to slow or stop vaccinia virus cell-to-cell spread.

• Drug dose-dependent inhibition of the cell-to-cell spread of vaccinia virus was observed (R2=0.9464) with an inhibition concentration of 50% and 90% at 15.7nM and 27nM concentrations of sabizabulin, respectively.

• In March, the FDA declined Veru's request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized adult COVID-19 patients.

• Price Action: VERU shares are up 0.50% at $1.00 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Once COVID-19 Candidate, Veru's Sabizabulin Shows Encouraging Action In Animal Studies Against Poxvirus originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.